[
  {
    "ts": "2025-09-15T13:03:29+00:00",
    "headline": "H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best defensive stocks to buy, according to Steve Cohen. On September 5, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $194 price target. The positive stance echoes the research firm’s confidence about the company’s promising lupus franchise. According to H.C. Wainwright, the lupus treatments litifilimab […]",
    "url": "https://finance.yahoo.com/news/h-c-wainwright-affirms-biogen-130329189.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "655e4a5a-744d-3582-99c3-0ab08d71f963",
      "content": {
        "id": "655e4a5a-744d-3582-99c3-0ab08d71f963",
        "contentType": "STORY",
        "title": "H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best defensive stocks to buy, according to Steve Cohen. On September 5, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $194 price target. The positive stance echoes the research firm’s confidence about the company’s promising lupus franchise. According to H.C. Wainwright, the lupus treatments litifilimab […]",
        "pubDate": "2025-09-15T13:03:29Z",
        "displayTime": "2025-09-15T13:03:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/38beb68055a72f3c3ae362be816dcc3a",
          "originalWidth": 1020,
          "originalHeight": 680,
          "caption": "H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z7_c67FYSs1QeSnShXFlmw--~B/aD02ODA7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/38beb68055a72f3c3ae362be816dcc3a.cf.webp",
              "width": 1020,
              "height": 680,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OZ6IrKR_ao5YyBJnHNPG0g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/38beb68055a72f3c3ae362be816dcc3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-affirms-biogen-130329189.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-affirms-biogen-130329189.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]